reason report
significantli beat consensu revenu ep driven
remark trikafta launch us trikafta sale reach
us beat consensu nearli estim
almost even exclud launch-rel
channel inventori build trikafta still beat consensu
estim total cystic fibrosi cf product revenu
beat consensu grow sequenti
yoy three cf drug kalydeco orkambi
symdeko miss consensu sequenti declin due faster
convers trikafta surprisingli symdeko experienc deeper
declin compar kalydeco orkambi base first quarter
perform believ trikafta like faster convers
cf drug well rapid adopt previous untreat
cf patient compani guid total cf product revenu
materi higher forecast consensu
howev guidanc annual revenu
appear account non-recur channel inventori build
offset underli growth seem unlik us
combin non-gaap sg expens guidanc
slightli higher consensu
estim non-gaap tax guidanc
larg line estim consensu beyond cf
compani program antitrypsin defici aatd captur
analyst investor attent call compani
like report proof-of-concept biomark data year addit
compani evalu multipl earli stage asset variou rare
diseas find hard attribut much real valu
stage pre-poc overal increment posit trikafta
penetr differ bucket cf patient includ exist
patient untreat patient success us launch
suggest tremend enthusiasm among patient physician
accommod stanc payer like posit impact eu
regulatori process well ultim reimburs approv
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
strong trikafta launch increas cf forecast price target
updat revenu expens forecast base
recent quarter manag guidanc commentari
total revenu forecast increas
chang primarili base significantli
faster revenu trajectori trikafta partial off-set rapid sale
eros three cf drug revis total revenu forecast
consensu higher
oper expens estim lower
higher base higher cog estim
partial off-set slightli lower sg base
chang pro forma dilut ep estim increas
larg unchang outer year revis ep estim
consensu consensu
updat multipl industri peer revis
price target versu previous maintain market
perform rate
year price history/av daili volume mil
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu
vertex cf portfolio loss exclus vertex launch success
iter cf medicin cloud disput price access
time reimburs revenu growth tend later expect
market expect vertex cf revenu grow steadili
consensu expect reflect forecast
robust perform compar consensu expect believ vertex geograph
revenu mix continu heavili weight us due
continu resist payer europ see dynam put current
consensu medium-term revenu estim risk probabl success tripl
combin market valuat account full expect
valu cf portfolio well risk-adjust opportun compani effort
antitrypsin defici aatd even posit view new dcf valuat
incorpor sustain oper margin requir
consider disciplin compani reput frugal
incorpor premium price target recogn vertex
might one attract larg cap growth asset sector howev
view reason acquisit premium would price compani nearli
like difficult pill swallow dilution-avers larg compani
revenu trikafta great start
vertex total cf product revenu beat consensu
forecast trikafta first two-month sale includ launch-
relat channel inventori build nearli consensu higher
forecast symdeko sale declin sequenti miss consensu
kalydeco q/q versu consensu orkambi
q/q versu consensu declin appear modest manag suggest
gross net adjust expect see improv
gross net orkambi patient switch trikafta
ep driven higher revenu partial off-set higher oper expens
gross margin slightli higher consensu estim vertex non-
total oper expens consensu higher
estim non-gaap expens consensu
estim non-gaap sg expens higher consensu
estim like due increment commerci support trikafta launch
compani non-gaap effect tax rate compar consensu
estim non-gaap dilut ep come
consensu estim
revenu guidanc materi higher consensu still seem
cf product revenu guidanc higher consensu
midpoint higher annual sale run rate
exclud launch-rel channel inventori build view revenu
guidanc easili achiev annual revenu alon without consid
materi trikafta uptak non-gaap sg expens guidanc
slightli higher consensu lower estim
compani explain call current revenu guidanc includ
limit revenu trikafta reimburs agreement outsid us non-
effect tax rate guidanc line estim
consensu manag indic vast major compani tax provis
non-cash expens nol fulli util
non-cf pipelin slowli attract invest attent
vertex current invest six emerg diseas area provid long-term pipelin
diversifi cf franchis consist antitrypsin defici
muscular dystrophi type diabet manag explain first candid
defici expect report phase data second candid
current phase kidney diseas program complet
phase studi start phase proof-of-concept poc studi pain
program alreadi establish poc compani continu evalu differ
molecul advanc best candid pivot stage addit vertex
collabor crisper report addit clinic data year on-going phase i/ii
gene edit program treatment sickl cell diseas beta
thalassemia compani continu gener larg amount free cash
expect continu build pipelin busi develop like rare diseas
area vertex disclos pain program suffer yet anoth setback
anoth clinic candid discontinu compani revert yet anoth back-
compound preclin develop
strong trikafta launch increas cf forecast price
updat revenu expens forecast base recent quarter
manag guidanc commentari total revenu forecast increas
chang primarili base
significantli faster revenu trajectori trikafta partial off-set rapid sale eros
three cf drug revis total revenu forecast consensu
higher oper expens estim
lower higher base higher cog
estim partial off-set slightli lower sg base chang
pro forma dilut ep estim increas larg unchang outer
year revis ep estim consensu
consensu updat multipl industri peer revis
price target versu previous maintain market perform rate
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl
price earn multipl higher growth larg cap biopharmaceut compani price
sale multipl mid larg cap high growth biopharmaceut compani
multipl ep nvo azn appli current
ep estim discount back year compani cost
equiti give valu one year use averag mid larg cap biotech price-
to-revenu multipl sale
appli revenu estim post-tripl discount back year
compani cost equiti give valu one year lastli dcf
valuat given wacc termin cash flow growth rate give present
valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kludger iambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cf tr
altern approach treat cf gene therapi final compani
histori spend much potenti earn expens diversifi acquisit
could undermin futur expect valu compani cf portfolio opportun
better-than expect perform includ realiz signific revenu
compani current cf dual combin market outsid us well acceler
clinic develop tripl combin regimen
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
ema approv
end age
older
submit snda us
age
sec gov compani websit present svbl analysi
data
data
start
brand
type event
event trial detail
date known
up/down
expect
report clinic data peopl two
mutat
addit data on-going phase studi
us snda submiss age
ema approv end age
evalu abil reduc protein
level urin
svb leerink llc research compani file
million
product sale po adjust
trikafta tripl comb ivacaftor tezacaftor elexacaftor approv
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal earn
current averag growth larg cap biopharma multipl ep nvo
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
